HDAC9 and medulloblastoma: For instance, it has been shown that the combination of JQ1 with a CDK2 inhibitor (Milciclib), an mTOR inhibitor (BEZ235), or a pan-HDAC inhibitor (Panobinostat) resulted in synergistic anti-cancer effects in MYC-driven group 3 medulloblastoma and amplified the potential of each of the combined agents [131,132,133].